<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590288</url>
  </required_header>
  <id_info>
    <org_study_id>PRESSURE GRADIENT MONITOR</org_study_id>
    <nct_id>NCT03590288</nct_id>
  </id_info>
  <brief_title>Dynamic Monitor of HVPG and Its Prognostic Value in Predicting Outcomes in Patients Undergoing TIPS</brief_title>
  <official_title>Dynamic Monitor of HVPG and Its Prognostic Value in Predicting Outcomes in Patients Undergoing TIPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pressure gradient plays an important role in prediction the outcomes of cirrhotic patients
      undergoing TIPS. An HVPG over 20 mmHg indicates a high risk of failure to control bleeding or
      preventing rebleeding, while patients with HVPG &lt;12 mmHg are free from the risk of variceal
      bleeding. This study aims to dynamically monitor the change of HVPG after TIPS procedure, and
      investigate its prognostic value in predicting patient outcome
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of hepatic venous pressure gradient / portosystemic pressure gradient</measure>
    <time_frame>The change of pressure gradient from immediately to 1 month after the procedure</time_frame>
    <description>The pressure gradient between portal vein and hepatic vein measured during portal angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variceal bleeding</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of clinically significant gastrointestinal variceal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of ascites detected by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shunt dysfunction</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of stenosis or occlusion of the TIPS stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other portal hypertension complications</measure>
    <time_frame>2 years</time_frame>
    <description>hepatorenal syndrome, jaudice, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy</measure>
    <time_frame>2 years</time_frame>
    <description>Hepatic encephalopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplant-free survivial</measure>
    <time_frame>2 years</time_frame>
    <description>Time from the procedure to the date of lost-to-follow-up or death or liver transplant</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>TIPS group</arm_group_label>
    <description>Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular intrahepatic portosystemic shunt</intervention_name>
    <description>Covered stents will be used, that will be dilated to 8 or 10 mm according to the hemodynamic response. The aim will be to reduce the portal pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.
Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.
After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.
Measurement of pressure gradient will be repeated within 3 days after the procedure and then at 1 month and 6 months after the procedure.
A TIPS revision will be performed once shunt dysfunction is suspected.</description>
    <arm_group_label>TIPS group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive cohort meeting the abovementioned criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis diagnosed by clinical examination, imaging or biopsy.

          -  Receiving TIPS due to variceal bleeding or refractory ascites

          -  Successful covered TIPS procedure

          -  Written informed consent

        Exclusion Criteria:

          -  Lactating or pregnant

          -  Malignancies

          -  Uncontrolled infection (&gt; grade 2)

          -  Severe cardiac, pulmonary or renal dysfunction

          -  Previously treated with TIPS

          -  Allergic to contrast agent

          -  History of spontaneous overt HE or recurrent HE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guohong Han, MD, PhD</last_name>
    <phone>86-29-84771537</phone>
    <email>hangh@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guohong Han, MD, PhD</last_name>
      <phone>86-29-84771537</phone>
      <email>hangh@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Guohong Han</investigator_full_name>
    <investigator_title>Head of Department of Digestive Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Transjugular intrahepatic portosystemic shunt</keyword>
  <keyword>Pressure gradient</keyword>
  <keyword>Outcome prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

